[Method for determining kallikrein of tissue origin in blood plasma and its clinical significance].
Based on a study of the kininogenase activity of the total plasma kallikrein in the presence of 3 concentrations of the soybean inhibitor trypsin (0.5, 1.0, 10.0 micrograms/ml) one can measure at a time the activity of tissue kallikrein (without specifying the source) and the activity of 3 forms of plasma kallikrein, including its adsorption on kaolin that characterizes the conformational structure of the enzyme. Examination of 10 healthy subjects and 136 patients revealed a 10 to 20-fold increase in the content of tissue kallikrein in plasma of 70% of diabetes mellitus patients and a 2.5 to 3-fold elevation in 50% of patients with chronic occupational bronchitis, and in 30% of patients suffering from chronic hepatitis. The method suggested makes it possible to have a better insight into the physiological and pathogenetic role of the kinin system and may be used for laboratory control over the treatment efficacy.
D004305:Dose-Response Relationship, Drug; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors / Q000097:blood*; D008722:Methods; D020840:Tissue Kallikreins; D014361:Trypsin Inhibitors / Q000494:pharmacology
D014361:Trypsin Inhibitors; D007610:Kallikreins; D020840:Tissue Kallikreins
Metod opredeleniia kallikreina tkanevogo proiskhozhdeniia v plazme krovi i ego znachenie dlia kliniki.